Could a vaccine stop cancer before it starts? lynch syndrome trial offers hope.
NCT ID NCT07163403
First seen Oct 31, 2025 · Last updated May 25, 2026 · Updated 24 times
Summary
This early-stage trial tests a personalized vaccine made from a person's own immune cells to prevent cancer in adults with Lynch syndrome, a genetic condition that raises cancer risk. The vaccine is designed to train the immune system to recognize and attack cells with specific protein errors. The study will enroll 20 participants and focus on safety and whether the vaccine triggers a targeted immune response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYNCH SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Laura Burunat
RECRUITINGBarcelona, Barcelona, 08036, Spain
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.